Dementia Drugs Market, By Drug Class (MAO Inhibitors, Cholinesterase Inhibitors, Glutamate Inhibitor, and Others), By Indication (Alzheimers Disease Dementia, Lewy Body Dementia, Parkinson Disease Dementia, and Others), By Route of Administration (Oral, I

Dementia Drugs Market, By Drug Class (MAO Inhibitors, Cholinesterase Inhibitors, Glutamate Inhibitor, and Others), By Indication (Alzheimers Disease Dementia, Lewy Body Dementia, Parkinson Disease Dementia, and Others), By Route of Administration (Oral, Intravenous, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Dementia drugs market growth is driven by rising cases of Alzheimer's and other forms of dementia worldwide. Dementia is a syndrome caused due to disorders that affect the brain, such as Alzheimer's disease or strokes. It is characterized by a gradual loss of cognitive functions like thinking, remembering and reasoning. Increasing awareness about diagnosis and availability of treatment options drive more people to seek medical help for dementia symptoms. Several pharmaceutical companies are investing heavily in research and development of effective drugs to slow down or stop the progression of dementia.

Market Dynamics

Dementia drugs market growth is primarily driven by rapidly aging global population, which increases the risk of neurodegenerative conditions. Rising healthcare expenditures in developing nations and intensive R&D efforts by biopharmaceutical firms further contribute to market expansion. However, high drug development costs, particularly due to the failure of many candidate molecules in late-stage trials and the complexity of these diseases, pose significant challenges. The recent approval of disease-modifying drugs that aim to impact disease etiology rather than merely alleviating symptoms presents substantial opportunities for manufacturers. Increased government support and funding for dementia research are encouraging market participants to innovate and develop new therapies. As the prevalence of dementia continues to rise, driven by demographic changes, the demand for effective treatments is expected to grow, positioning the market for significant advancements.

Key features of the study

• This report provides in-depth analysis of the global dementia drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global dementia drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Biogen, Eisai Co., Ltd., Novartis AG, Cipla, H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Mapi-Pharma Ltd., AbbVie, Inc., DAIICHI SANKYO COMPANY, LIMITED., and F. Hoffmann-La Roche Ltd
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global dementia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dementia drugs market

Market Segmentation

• By Drug Class Insights (Revenue, USD Bn, 2019 – 2031)
• MAO Inhibitors
• Cholinesterase Inhibitors
• Glutamate Inhibitor
• Others
• By Indication Insights (Revenue, USD Bn, 2019 – 2031)
• Alzheimer’s Disease Dementia
• Lewy Body Dementia
• Parkinson Disease Dementia
• Others
• By Route of Administration Insights (Revenue, USD Bn, 2019 – 2031)
• Oral
• Intravenous
• Others
• By Distribution Channel Insights (Revenue, USD Bn, 2019 – 2031)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Regional Insights (Revenue, USD Bn, 2019 – 2031)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Biogen
• Eisai Co., Ltd.
• Novartis AG
• Cipla
• Lundbeck A/S
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Viatris Inc.
• Mapi-Pharma Ltd.
• AbbVie, Inc.
• DAIICHI SANKYO COMPANY, LIMITED.
• F.Hoffmann-La Roche Ltd